Business Context and Reporting Period
This Form 6-K filing by GSK plc (GSK) reports a transaction in its own shares conducted on August 11, 2025, and filed on August 12, 2025. The filing details a share repurchase executed through Merrill Lynch International as part of the company's existing buyback programme, which was initiated via a non-discretionary agreement on June 4, 2025.
Key Financial Metrics
The filing focuses exclusively on capital allocation activities regarding share repurchases. No revenue, profit, cash flow, or debt metrics are provided in this specific document.
- Shares Purchased (August 11, 2025): 494,426 ordinary shares.
- Price Range: Lowest price paid was 1,400.00 GBp; highest price paid was 1,413.50 GBp.
- Volume-Weighted Average Price (VWAP): 1,405.33 GBp.
- Trading Venue: London Stock Exchange (XLON).
- Cumulative Buyback (Since June 4, 2025): 22,402,993 ordinary shares.
- Treasury Shares Held: 240,537,376 ordinary shares.
- Shares in Issue (Excluding Treasury): 4,074,853,870 ordinary shares.
- Treasury Voting Rights: 5.90% of total voting rights.
Material Changes
The filing reports a reduction in the number of shares in issue and an increase in treasury shares held by the company. The total number of voting rights remains 4,074,853,870, as treasury shares do not carry voting rights. The percentage of voting rights attributable to treasury shares stands at 5.90% following this transaction.
Guidance, Outlook, and Risks
The filing contains no new financial guidance or operational outlook. It includes a standard cautionary statement regarding forward-looking statements, noting that actual results may differ materially from projections due to risks and uncertainties. These risks are referenced as being described in the "Risk Factors" section of GSK's Annual Report on Form 20-F for 2024 and its Q2 Results for 2025.
Investor Verification Checklist
- Verify the total remaining authorization under the buyback programme announced on June 4, 2025.
- Confirm the total cost of the repurchase programme to date by aggregating transaction values.
- Review the "Risk Factors" in the 2024 Form 20-F and Q2 2025 results for context on the company's financial health and strategic priorities.
- Monitor future filings to track the pace of the buyback programme and any changes to the treasury share percentage.